共识指南/ Consensus Guide

2005AAP 美国1型糖尿病儿童患者视网膜病变筛查 返回>>

浏览量:128

发布日期:2005/01/01

英文标题:2005AAP Screening for Retinopathy in the Pediatric

作 者:美国儿科学会(AAP,American

出 处:Pediatrics. 2005 Jul;116(1):270-3.

内容介绍:

        Type 1 diabetes mellitus is one of the most common metabolic disorders in children, with a prevalence of approximately 2 per 1000 schoolaged children in the United States. The prevalence of type 1 diabetes mellitus increases with age, and the

        overall incidence of the disease may be increasing. Although the incidence of type 2 diabetes in children is increasing, there are no data or guidelines regarding

        ophthalmic screening in children with this disorder. Diabetic retinopathy (DR) is one of the most important complications of type 1 diabetes mellitus, representing the leading cause of blindness in young adults. There are 3 main components of a strategy to minimize the risk of visual loss attributable to DR: (1) provide the most effective treatment of the underlying metabolic disorder and its comorbidities; (2) develop optimal treatment modalities for patients with ocular disease; and (3) identify risk factors for the development of ocular disease and implement effective

screening programs to identify at-risk patients. The first 2 have been evaluated in well-conducted, large, prospective trials.


指南下载:

您尚未登录,马上 登录 ,可下载本指南!



2005AAP 美国1型糖尿病儿童患者视网膜病变筛查

浏览量:128

发布日期:2005/01/01

英文标题:2005AAP Screening for Retinopathy in the Pediatric

作 者:美国儿科学会(AAP,American

出 处:Pediatrics. 2005 Jul;116(1):270-3.

内容介绍:

        Type 1 diabetes mellitus is one of the most common metabolic disorders in children, with a prevalence of approximately 2 per 1000 schoolaged children in the United States. The prevalence of type 1 diabetes mellitus increases with age, and the

        overall incidence of the disease may be increasing. Although the incidence of type 2 diabetes in children is increasing, there are no data or guidelines regarding

        ophthalmic screening in children with this disorder. Diabetic retinopathy (DR) is one of the most important complications of type 1 diabetes mellitus, representing the leading cause of blindness in young adults. There are 3 main components of a strategy to minimize the risk of visual loss attributable to DR: (1) provide the most effective treatment of the underlying metabolic disorder and its comorbidities; (2) develop optimal treatment modalities for patients with ocular disease; and (3) identify risk factors for the development of ocular disease and implement effective

screening programs to identify at-risk patients. The first 2 have been evaluated in well-conducted, large, prospective trials.


指南下载:

您尚未登录,马上 登录 ,可下载本指南!